Journal article · 2024 · Open access

The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?

Helena Kanďárová, Peter Pôbiš

Frontiers in Toxicology, 5, 1337468 · Published 8 January 2024 · DOI 10.3389/ftox.2023.1337468

Free PDFView at the publisherCite this paper

In brief

“The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?” is a 2024 journal article by Helena Kanďárová and Peter Pôbiš, published in Frontiers in Toxicology. OpenAlex counts 127 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Toxicology.

Citations
127
Most cited in
2026 (60)
Field-weighted impact
63.67
References
11
Authors
2

Abstract

Biocompatibility testing ensures the safety of medical devices by assessing their compatibility with biological systems and their potential to cause harm or adverse reactions. Thus, it is a critical part of the overall safety evaluation process for medical devices. Three primary types of biocompatibility tests—cytotoxicity, irritation, and sensitisation assessment—are standard for nearly all medical devices. However, additional biocompatibility tests, such as genotoxicity, systemic toxicity, hemocompatibility, and implantation studies, may also be necessary, depending on the device’s nature and intended use. The testing is partly conducted in vitro , but the industry still heavily relies on animal experiments. Compared to other industrial sectors, implementing alternatives in medical device biocompatibility testing has been notably slower. This delay can be attributed to the absence of specific validation processes tailored to medical devices and the resulting hesitation regarding the predictive capacity of these alternative methods despite their successful applications in other domains. This review focuses on the progress and obstacles to implementing new approach methodologies in the areas of cytotoxicity, irritation and sensitisation testing of medical devices. While challenges persist in adopting these innovative methods, the trend towards embracing alternatives remains robust. This trend is driven by technological advancements, ethical considerations, and growing industrial interest and support, all collectively contributing to advancing safer and more effective medical devices.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kanďárová, H., & Pôbiš, P. (2024). The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet? Frontiers in Toxicology, 5, 1337468. https://doi.org/10.3389/ftox.2023.1337468

MLA 9

Kanďárová, Helena, and Peter Pôbiš. “The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?” Frontiers in Toxicology, vol. 5, 2024, p. 1337468. https://doi.org/10.3389/ftox.2023.1337468.

Chicago

Kanďárová, Helena and Peter Pôbiš. 2024. “The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?” Frontiers in Toxicology 5: 1337468. https://doi.org/10.3389/ftox.2023.1337468.

Harvard

Kanďárová, H. and Pôbiš, P. (2024) ‘The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?’, Frontiers in Toxicology, 5, p. 1337468. doi:10.3389/ftox.2023.1337468.

IEEE

H. Kanďárová and P. Pôbiš, “The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?,” Frontiers in Toxicology, vol. 5, p. 1337468, 2024, doi: 10.3389/ftox.2023.1337468.

BibTeX

@article{kandarova2024three,
  title     = {{The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?}},
  author    = {Kanďárová, Helena and Pôbiš, Peter},
  journal   = {Frontiers in Toxicology},
  year      = {2024},
  volume    = {5},
  pages     = {1337468},
  doi       = {10.3389/ftox.2023.1337468},
  url       = {https://doi.org/10.3389/ftox.2023.1337468}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202111
20241212
20255454
20266060

Its field-weighted citation impact is 63.67: it has been cited 63.67 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Veterinary › Small Animals › Animal testing and alternatives

  • biocompatibility testing
  • medical devices
  • alternatives to animal testing
  • 3Rs
  • cytotoxicity assay
  • in vitro methods
  • new approach methodologies
  • method validation

Work with this paper

Most-cited papers in Veterinary

All highly cited Veterinary papers

Questions about this paper

How do I cite this paper in APA style?

Kanďárová, H., & Pôbiš, P. (2024). The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet? Frontiers in Toxicology, 5, 1337468. https://doi.org/10.3389/ftox.2023.1337468

How many times has this paper been cited?

127 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Frontiers in Toxicology.

Who wrote this paper?

Helena Kanďárová, Peter Pôbiš.

What is the DOI of this paper?

10.3389/ftox.2023.1337468. The permanent link is https://doi.org/10.3389/ftox.2023.1337468.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.